Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and Ipilimumab with or without SBRT for Metastatic Merkel Cell Carcinoma
NCT03071406Phase 2Active, not recruiting
- Sponsor
- Moffitt Cancer Center
- Start
- Mar 2017
- Primary completion
- Apr 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, ipilimumab in Merkel cell carcinoma (MCC), sponsored by Moffitt Cancer Center. Started Mar 2017; status: active, not recruiting.
02
Drugs
nivolumabipilimumab
03
Conditions
Merkel cell carcinoma (MCC)
Beyond the preview
Go deeper on NCT03071406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03071406.